New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis...
iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)
Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram...
New Research Confirms iCAD’s ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists’ Workflow
Studies presented at two leading breast imaging conferences demonstrate ProFound AI helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision NASHUA, N.H. – April 19, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced...
iCAD Launches New Initiatives Leveraging Unique Capabilities of its Robust Product Portfolio to Reduce Health Care System Pressures During the COVID-19 Pandemic
ProFound AI can assist radiologists in prioritizing patients for breast cancer screening and address the growing mammography backlog Xoft breast IORT offers single-fraction therapy alternative to weeks of daily radiation, reducing resources needed and minimizing patients’ risk of COVID-19 exposure Today, iCAD launched new initiatives to address emerging...